Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer

Authors

Robert L. Coleman, University of Texas M.D. Anderson Cancer Center
Andrea R. Hagemann, Washington University School of Medicine in St. Louis
et al.

Journal

The New England Journal of Medicine

Publication Date

2019

Volume

381

Issue

25

First Page

2403

Last Page

2415

Document Type

Open Access Publication

DOI

10.1056/NEJMoa1909707

Rights and Permissions

Coleman, R. L., Fleming, G. F., Brady, M. F., Swisher, E. M., Steffensen, K. D., Friedlander, M., . . . Bookman, M. A. (2019). Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. New England Journal of Medicine, 381(25), 2403-2415. doi:10.1056/NEJMoa1909707 https://www.nejm.org/doi/full/10.1056/NEJMoa1909707 Copyright © 2019, Massachusetts Medical Society

Recommended Citation

Coleman, Robert L.; Hagemann, Andrea R.; and al., et, "Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer." The New England Journal of Medicine. 381, 25. 2403 - 2415. (2019).
https://digitalcommons.wustl.edu/open_access_pubs/8708